Nabors Industries Ltd. (NBR) Analysts See $-0.33 EPS; Last Week Aerie Pharmaceuticals, Inc. (AERI) Analysts

February 21, 2018 - By Richard Conner

Analysts expect Nabors Industries Ltd. (NYSE:NBR) to report $-0.33 EPS on February, 27 after the close.They anticipate $0.03 EPS change or 10.00% from last quarter’s $-0.3 EPS. After having $-0.42 EPS previously, Nabors Industries Ltd.’s analysts see -21.43% EPS growth. The stock decreased 1.66% or $0.11 during the last trading session, reaching $6.51. About 6.24 million shares traded. Nabors Industries Ltd. (NYSE:NBR) has risen 32.66% since February 21, 2017 and is uptrending. It has outperformed by 15.96% the S&P500.

Among 15 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aerie Pharmaceuticals had 47 analyst reports since August 7, 2015 according to SRatingsIntel. On Monday, December 18 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Cowen & Co maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Wednesday, August 2. Cowen & Co has “Buy” rating and $10000 target. The firm earned “Buy” rating on Friday, August 7 by Cantor Fitzgerald. H.C. Wainwright maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Wednesday, August 2. H.C. Wainwright has “Buy” rating and $6900 target. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given on Monday, October 16 by Canaccord Genuity. The stock has “Buy” rating by Canaccord Genuity on Wednesday, August 16. The stock has “Buy” rating by H.C. Wainwright on Tuesday, September 20. The stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by H.C. Wainwright on Thursday, July 20. The firm has “Buy” rating given on Wednesday, October 11 by Stifel Nicolaus. The rating was maintained by Cowen & Co with “Buy” on Thursday, October 5. See Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) latest ratings:

16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain
18/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $77.0 Maintain
16/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $69.0 Maintain
09/11/2017 Broker: Cowen & Co Rating: Buy New Target: $100.0 Maintain
24/10/2017 Broker: Guggenheim Rating: Buy New Target: $80 Initiates Coverage On
16/10/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $65 New Target: $73 Maintain
11/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $70.0 Maintain

Among 34 analysts covering Nabors Industries Ltd. (NYSE:NBR), 26 have Buy rating, 0 Sell and 8 Hold. Therefore 76% are positive. Nabors Industries Ltd. had 109 analyst reports since August 6, 2015 according to SRatingsIntel. Citigroup maintained Nabors Industries Ltd. (NYSE:NBR) rating on Friday, August 14. Citigroup has “Neutral” rating and $13 target. The stock has “Market Perform” rating by BMO Capital Markets on Monday, August 10. Cowen & Co maintained the shares of NBR in report on Thursday, February 18 with “Outperform” rating. The stock of Nabors Industries Ltd. (NYSE:NBR) earned “Neutral” rating by Credit Suisse on Wednesday, June 1. The company was upgraded on Tuesday, November 29 by Tudor Pickering. The stock of Nabors Industries Ltd. (NYSE:NBR) earned “Hold” rating by BMO Capital Markets on Tuesday, September 5. The company was initiated on Wednesday, January 18 by SunTrust. Credit Suisse maintained the shares of NBR in report on Friday, September 4 with “Neutral” rating. The company was upgraded on Monday, September 19 by CapitalOne. The firm has “Hold” rating given on Sunday, September 17 by Piper Jaffray.

Investors sentiment decreased to 1.01 in Q3 2017. Its down 0.08, from 1.09 in 2017Q2. It dived, as 45 investors sold Nabors Industries Ltd. shares while 87 reduced holdings. 42 funds opened positions while 91 raised stakes. 274.98 million shares or 2.16% more from 269.17 million shares in 2017Q2 were reported. Advisory Service Ntwk Limited Liability Co holds 500 shares. Caxton Assocs Ltd Partnership reported 1.05M shares stake. Texas Permanent School Fund has 0.02% invested in Nabors Industries Ltd. (NYSE:NBR) for 208,647 shares. Indexiq Limited Liability Corp owns 7,668 shares. M&T Financial Bank Corporation accumulated 18,239 shares. Metropolitan Life Ins Com Ny owns 268,631 shares or 0.01% of their US portfolio. Waddell And Reed Fincl Inc reported 1.83M shares stake. Pekin Singer Strauss Asset Mngmt Il reported 0.04% stake. Raymond James Fincl Svcs Advsr holds 0% or 72,155 shares in its portfolio. Aviance Cap Limited Liability Co owns 10,233 shares or 0.01% of their US portfolio. Commonwealth Of Pennsylvania Public School Empls Retrmt invested in 0.01% or 47,070 shares. Strs Ohio holds 2.51M shares. Mitchell Group reported 2.36 million shares or 3% of all its holdings. Thompson Davis & owns 0.01% invested in Nabors Industries Ltd. (NYSE:NBR) for 350 shares. Moreover, Quantbot Tech Limited Partnership has 0.03% invested in Nabors Industries Ltd. (NYSE:NBR) for 41,646 shares.

Nabors Industries Ltd. provides drilling and rig services. The company has market cap of $2.07 billion. The firm offers equipment manufacturing, rig instrumentation, optimization software, and directional drilling services; and It provides patented steering systems and rig instrumentation software systems, including ROCKIT directional drilling system that provides data collection services to gas and oil exploration and service companies; REVit control system, a stick slip mitigation system; RIGWATCH software, which monitors a rig's real-time performance and offers daily reporting for drilling operations; and DRILLSMART software that allows the drilling system to adapt to operating parameters and drilling conditions. It currently has negative earnings. The firm also provides measurement while drilling systems and services; makes and sells top drives, catwalks, wrenches, draw works, and other drilling related equipment; and offers well-site services, such as engineering, transportation and disposal, construction, maintenance, well logging, directional drilling, data collection, and other support services.

The stock decreased 1.28% or $0.7 during the last trading session, reaching $54.2. About 284,595 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has risen 180.20% since February 21, 2017 and is uptrending. It has outperformed by 163.50% the S&P500.

Investors sentiment increased to 1.73 in 2017 Q3. Its up 0.56, from 1.17 in 2017Q2. It improved, as 14 investors sold Aerie Pharmaceuticals, Inc. shares while 41 reduced holdings. 26 funds opened positions while 69 raised stakes. 34.42 million shares or 8.89% more from 31.61 million shares in 2017Q2 were reported. Parkside National Bank & Tru holds 0% or 193 shares. Laurion Capital Mngmt Limited Partnership reported 4,800 shares stake. Dafna Cap Mngmt Ltd Liability Com invested in 116,770 shares or 3.52% of the stock. The Illinois-based Citadel Advsr Limited Com has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Raymond James And Assocs reported 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Kazazian Asset Ltd Liability invested in 0.87% or 14,577 shares. Alliancebernstein Limited Partnership stated it has 414,730 shares. Alps Advisors, a Colorado-based fund reported 35,790 shares. Waddell & Reed Financial stated it has 463,354 shares. Hanseatic Mngmt Inc invested in 16 shares or 0% of the stock. Connecticut-based Aqr Mgmt Ltd Co has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 35,000 are owned by Highland Ltd Partnership. Prudential Fincl Incorporated holds 0% of its portfolio in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 56,520 shares. 120,932 are owned by Rhenman & Ptnrs Asset Mngmt. Tower Research Llc (Trc) holds 0.02% or 4,651 shares in its portfolio.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.13 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.